logo dark logo light logo
  • Home
  • About Us
    • Background
    • Investment Strategy
    • Team
  • Portfolio
  • News
  • Contact
  • Investor Login
mobile-logo
  • Home
  • About Us
    • Background
    • Investment Strategy
    • Team
  • Portfolio
  • News
  • Contact
  • Investor Login
 

News

28 Mar 2018
by admin
in Uncategorized
Comments
Tempest Therapeutics Closes $70 Million Series B Financing – Cancer immunology programs launched from Versant’s Inception Discovery Engine –
26 Mar 2018
by admin
in Uncategorized
Comments
ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study
19 Mar 2018
by admin
in Uncategorized
Comments
resTORbio Announces Formation of Clinical Advisory Board
12 Mar 2018
by admin
in Uncategorized
Comments
Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
01 Mar 2018
by admin
in Uncategorized
Comments
Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting
21 Feb 2018
by admin
in Uncategorized
Comments
Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9

4560 Jinke Road, Jinchuang Plaza, Building 1, 4/F, Zhangjiang Hi-tech Park, Pudong, Shanghai, 201210 P.R. China
Phone: +86 21 6163 2598  |  Fax: +86 21 6163 2570  |  Email: info@quancapital.com

© Quan Capital. All rights reserved. Credit: Website Design